Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ: MDGL), could bode well for Novo Nordisk A/S (NYSE: ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) ...

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the ...

Madrigal Pharmaceuticals is working to expand its markets and roll out its first drug. Sales of its medicine look good so far, and there isn't any competition yet. Developing a competitive ...

JMP Securities raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $427 from $415 and keeps an Outperform rating on the shares ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of $6.66 billion, has positioned itself as a frontrunner in the treatment of nonalcoholic steatohepatitis (NASH) with its ...

When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...